Prime Healthcare (“Prime”) and Verity Health System (“Verity”) announced today that the U.S. Bankruptcy Court for the Central District of California in Los Angeles has approved the Asset Purchase Agreement for the sale of St. Francis Medical Center (“St. Francis”) in Lynwood, California. Under the agreement, Prime will acquire St. Francis for a net consideration of over $350 million, including a $200 million ($200,000,000) base price and $15 million in payroll and benefits for staff.
“St. Francis Medical Center plays a crucial role in providing high quality care for patients in Lynwood and the surrounding communities,” said Rich Adcock, CEO of Verity Health. “Prime has time and time again saved hospitals to support communities. We are confident that Prime will continue this record of excellence and look forward to working in partnership through the sale close process.”
NEWARK, NJ - One of the most promising treatments for COVID-19 is being made available through an expanded access program at Prime Healthcare’s Saint Michael’s Medical Center in Newark.Remdesivir, considered by the World Health Organization to be the most promising drugs to treat COVID-19, was developed by Gilead Sciences to treat Ebola.
The antiviral drug is effective against two other coronaviruses that cause deadly respiratory diseases – SARS and MERS – and is in five large clinical trials for the treatment of COVID-19.Saint Michael’s is one of only a handful of sites in the world to participate in the expanded access program, which will allow the hospital to administer remdesivir to critically ill patients who are on ventilators.
The hospital has been a leader in clinical infectious disease research and has worked with Gilead since the pharmaceutical company was founded in 1987.
There is currently no treatment approved for COVID-19, a disease that has infected more than 1.2 million worldwide and resulted in nearly 70,000 deaths.Saint Michael’s is located in the New York metropolitan area, which has become ground zero for COVID-19 infection in the United States.
In the last week, Saint Michael’s has seen a spike in patients with the disease.
Currently, nearly every bed in the hospital is filled with patients who have tested positive for the virus.
Prime Healthcare scored a key victory in its breach of contract lawsuit with Humana, which allegedly underpaid or denied payment for services provided to Medicare Advantage beneficiaries.
The global wood coatings market features a highly competitive landscape owing to the presence of a plethora of companies competing against one another, notes Transparency Market Research (TMR).
Top players in the wood coatings market increasingly resort to forward integration strategies to gain substantial competitive benefits, which may help them to retain their stronghold over the assessment period.
View exclusive Global strategic Business report - https://www.transparencymarketresearch.com/wood-coating-market.htmlTMR finds that the wood coatings market is also fairly consolidated as the top four players held a combined share of nearly 60.0% in 2016.
Some of the other companies operating in the global wood coatings market are the Dow Chemical Company, Nippon Paints Holdings, the Asian Paints, and BASF SE.The global wood coating market stood at US$8.625 billion in 2016 and is projected to rise at a promising 8.3% CAGR during 2017–2025.
The growth is driven by the use of these resins in the myriad applications, attributed to them being largely scratch- and humidity- resistant.Of all the key regional markets, Asia Pacific held the majority of share in the global market for wood coatings.
The growth is increasingly fueled by the burgeoning demand for wood coating applications, largely from the sales of furniture across.